TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C TO EVALUATE R-842

治疗慢性丙型肝炎患者以评估 R-842

• 批准号: 5215913
• 负责人: ROBERT L CARITHERS
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5215913
• 关键词: RNA; antiviral agents; blood chemistry; chronic disease /disorder; clinical research; clinical trial phase I; dosage; drug adverse effect; drug screening /evaluation; hepatitis C virus; human subject; human therapy evaluation; interferon alpha; pharmacokinetics; virus infection mechanism

R-842 is an oral alpha interferon inducer. The purpose of this phase I study is to determine the safety and efficacy of R842 in patients with chronic hepatitis C virus infection. Pharmacokinetic studies will be done after the first and last doses. Efficacy will be monitored using quantitative HCV RNA levels and safety will be monitored by weekly clinic visits and blood draws.

R-842是一种口服α干扰素诱导剂。 第一阶段的目的是 研究的目的是确定R842在以下患者中的安全性和有效性： 慢性丙型肝炎病毒感染 药代动力学研究将 在第一次和最后一次注射后。 将使用以下方法监测疗效 每周诊所将监测定量HCV RNA水平和安全性 探访和抽血